Anika Therapeutics (ANIK) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Anika Therapeutics (ANIK) is Neutral.

The composite score behind that read is +0.15, weighing +0.29 of bullish evidence against -0.20 bearish.

Anika Therapeutics last closed at $19.58, +1.82% on the session.

Against the IVW growth benchmark the position is +1.02% over the forecast window.

The read is built from 15 underlying insights — 7 bullish and 8 bearish.

Agreement across those insights is 53%.

2 graded predictions for ANIK so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Anika Therapeutics in the 38th percentile on return on equity, where 100 is best.

Anika Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $257.36M.

StockMap tracks Anika Therapeutics as the 224th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Anika Therapeutics ranks 26th of 381 in the group, against a group median of -0.08.